FDA approves two new indications for Epaned

DENVER — Silvergate Pharmaceuticals on Monday announced that the Food and Drug Administration approved Epaned (enalapril maleate Powder for oral solution) for the treatment of symptomatic heart failure, as well as the treatment of asymptomatic left ventricular dysfunction. The drug was previously approved to treat high blood pressure in patients older than one month of age. 
 
"Now with three indications, Epaned is available to help more patients who need the proven benefits of enalapril in an FDA-approved powder for oral solution, thereby ensuring that they are receiving a medicine that meets the highest quality standards," said Frank Segrave, president and CEO, Silvergate Pharmaceuticals.
 
 
Login or Register to post a comment.